Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 6681)

VOLUNTARY ANNOUNCEMENT ENTERING INTO STRATEGIC COOPERATION AGREEMENT TO EXPAND INTO THE SINGAPORE MARKET AND PROMOTE INTERNATIONAL POSITIONING

This announcement is made by BrainAurora Medical Technology Limited 脑动极光医疗科技有限公司 (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis for the purposes of keeping the investors informed of the latest update on the business developments of the Group.

The board of directors (the "**Board**") of the Company is pleased to announce that the Company has recently entered into a strategic cooperation agreement (the "**Agreement**") with Natural Health Solutions Programme Group Holdings (萊賀思寶健康管理控股集團) ("**NHS**"), pursuant to which both parties thereto will carry out synergistic cooperation in product promotion and market expansion in the Singapore market as their joint efforts to promote the development of the digital health industry.

BACKGROUND AND CONTENT OF COOPERATION

As one of the developed economies in Asia, Singapore is facing the challenge of a rapidly aging population. According to data from the Singapore government, in line with a growing proportion of the population aged 65 and above, the incidence of senile cognitive impairment (dementia) also becomes increasingly significant. The Singapore government is proactively promoting national programmes such as "Healthier SG" and "Dementia-Friendly Singapore", which is aimed at encouraging early screening and full-cycle health management, and providing a favourable policy environment and market foundation for cognitive impairment digital therapeutics products.

As a pioneer in China's cognitive impairment digital therapeutics market, the Company's core product, the "Brain Function Information Management Platform Software System", is the first cognitive impairment digital therapeutics product in China to receive regulatory approval and has been included in the provincial medical insurance reimbursement lists of 30 provinces across China. NHS is a professional health management service institution headquartered in Singapore, possessing the self-developed SC Health AI digital health assessment system, with a service network covering community healthcare and the health management market.

Pursuant to the Agreement, the cooperation between the parties thereto mainly includes the following: (I) product promotion cooperation: the Company is responsible for the localization and adaptation, system implementation, and personnel training support of the cognitive impairment digital therapeutics products in Singapore; NHS will rely on all its offline stores and membership resources to conduct targeted recommendations of the Company's products to target users, and take responsibility for the full-process service, including product introduction, trial guidance, purchase conversion, and after-sales support; and (II) market expansion synergy: both parties thereto will integrate resources such as products, channels, brands, and technologies to jointly explore the Singapore market, focusing on promoting the entry of the Company's products into Singapore's top private hospitals and public hospital systems, thereby enhancing the application and popularity of the products in the local medical system.

The Agreement is a framework agreement entered into by both parties in relation to collaborations in the Singapore market, and the specific performance details thereof will be subject to further implementation rules to be agreed upon by both parties.

REASONS FOR AND BENEFITS OF THE COOPERATION

The Board believes that this cooperation will present long-term development opportunities to the Company, thereby creating sustainable value for the shareholders, specifically: (I) deepening international positioning and expanding overseas markets: the Company has commenced product promotion and operations in the Hong Kong and Macau regions, preliminarily accumulating experience in overseas markets. This cooperation with NHS marks the official launch of the Company's market positioning and business development in the Southeast Asia region. This move helps to systematically export the digital therapeutics experience and technical system accumulated by the Company in the China market to other regions that demonstrate promising market size and strong policy support, further expanding the Company's international brand influence and business coverage, and enhancing its global presence; and (II) enhancing brand influence and commercial network: this cooperation further strengthens the Company's brand authority and professional image in the digital healthcare sector. Leveraging NHS's health management network in Singapore, the Company can accelerate the implementation of products in local medical institutions, shorten the market introduction cycle, and expand into diversified markets such as digital health management.

IMPLICATIONS UNDER THE LISTING RULES

To the best of the knowledge and belief of the Company, NHS and its respective shareholders are independent of and not connected with the Company and its connected persons (as defined in the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**")). The transaction contemplated under this cooperation do not constitute any connected transaction of the Company under Chapter 14A of the Listing Rules, nor does it constitute any notifiable transaction of the Company under Chapter 14 of the Listing Rules.

By order of the Board
BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
Mr. Tan Zheng
Chairman and Executive Director

Hong Kong, December 29, 2025

As of the date of this announcement, the Board comprises: (i) Mr. Tan Zheng as executive director; (ii) Mr. Li Sirui, Ms. Li Mingqiu and Mr. Deng Feng as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Tu Lei as independent non-executive directors.